BRAF and liposarcoma: The former covers BRAF V600E mutation which is present in about 20% of the FDCS case, while the latter includes MDM2 amplification [19], and this genetic alteration leads us to the most important entity in the differential diagnosis, namely the dedifferentiated liposarcoma (DLS).